Previous 10 | Next 10 |
Bio-Path Holdings, Inc. (BPTH) Q2 2021 Earnings Conference Call August 13, 2021 08:30 AM ET Company Participants Peter Nielsen - President, CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Will O’Connor - Stern IR Conference Call Participants Yi Chen - H.C. Wai...
HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial ...
HOUSTON, Aug. 06, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera Pharmaceuticals (IDRA) +11%.Insp...
HOUSTON, June 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that...
Start Time: 08:30 End Time: 08:56 Bio-Path Holdings, Inc. (BPTH) Q1 2021 Earnings Conference Call May 14, 2021, 08:30 AM ET Company Participants Peter Nielsen - President, CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Will O’Connor - Stern IR Conference Call...
Bio-Path (BPTH): Q1 GAAP EPS of -$0.43 beats by $0.06.As of March 31, 2021, the Company had cash of $30.8 million, compared to $13.8 million as of December 31, 2020.Press Release For further details see: Bio-Path EPS beats by $0.06
HOUSTON, May 14, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize ® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial r...
HOUSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a ...
HOUSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the publication of...
News, Short Squeeze, Breakout and More Instantly...
Bio-Path Holdings Inc. Company Name:
BPTH Stock Symbol:
NASDAQ Market:
Bio-Path Holdings Inc. Website:
Marks Meaningful Progress Across Key Clinical Trials in Multiple Cancer Indications Completes Development of Oncology Molecular Biomarkers and Prepares for Preclinical Obesity Studies HOUSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnolog...
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...